Imaging Diagnostic Submits First Interim Report to FDA
FORT LAUDERDALE, Fla., Mar. 24 -- Imaging Diagnostic Systems Inc. has submitted to the US Food and Drug Administration an interim report on ongoing clinical investigation trials involving its laser-based breast imaging device, the CTLM. The CTLM utilizes laser technology and patented computed algorithms to create contiguous cross-sectional slice images of the breast without the use of breast compression or x-rays.
The report contains statistical results as well as comparative mammography and CTLM images of malignant and benign case studies. The case studies were acquired from Imaging Diagnostic's clinical sites, Nassau County Medical Center and the University of Virginia Hospital.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024